Holland & Knight advised Savara on the offering.Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $100 million underwritten…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Laura Testa
…
This content is for Standard 1 Year members only. LoginJoin Now